In concordance with this, BRAF-mutant CRC cell lines express higher levels of EGFR than BRAF-mutant melanoma cell lines, which may explain the difference in the efficacy of BRAF inhibitors in the clinical setting among cancer types. This evidence concerns the gene EGFR and cancer.